Executive Summary

Oct 2019
PROSPECTS
Less severe flu season in 2019 leads to weaker demand for relevant products

Sales of cough, cold and allergy (hay fever) remedies in the Netherlands are mainly reliant on seasonal factors. One important factor is the flu season, when the cold, damp weather causes national flu levels to rise in a country that enjoys a more moderate climate than many of its European neighbours.

Rising incidence of hay fever continue to support performance of antihistamines/allergy remedies

One other important season for sales of cough, cold and allergy (hay fever) remedies is spring, when Dutch consumers are more likely to suffer from certain allergies, particularly hay fever. While incidence of hay fever fluctuate depending on specific types of pollen that affect different consumers, the general pattern of seasonal behaviour linked to allergies is supporting ongoing demand for antihistamines/allergy remedies, which is predicted to continue into the forecast period.

Solid presence for private label with potential for further penetration

Private label had a solid presence in cough cold and allergy (hay fever) remedies in 2019, although its value share was much lower than in analgesics. Supermarket chains such as Albert Heijn and Jumbo, continued to gain value share of distribution of this category, in addition to offering their own private label lines, supported by consumers’ increasing confidence in choosing alternatives to major, more expensive brands.

COMPETITIVE LANDSCAPE
Lofthouse retains overall leadership, present in largest category of medicated confectionery

Lofthouse of Fleetwood retained its overall leadership of cough, cold and allergy (hay fever) remedies in 2019, due to its ongoing strong position in the largest category in value sales terms of medicated confectionery. While its leading brand Fisherman's Friend retained its value share, it recorded undynamic sales growth, while competing brands such as Vicks from Procter & Gamble, and Pervasco BV, recorded stronger performances in 2019, gaining both value share from private label and smaller brands.

Otrivin remains dominant leader of nasal sprays but loses share to natural positioning of competing brand A Vogel

GSK Consumer Healthcare remained in second position in overall cough, cold and allergy (hay fever) remedies in 2019, offering its brand Otrivin, which is present in a number of categories including its leadership of nasal sprays, in addition to antihistamines/allergy remedies (systemic) with Otrivin Azelastine which continues to perform strongly, and paediatric cough/cold remedies. However, the player continued to notably lose share within nasal sprays to A Vogel from Biohorma BV, which gained further ground in 2019 due to its natural positioning, as its produced from ecologically-grown medicinal herbs and plants.

Concerns over sugar content of cough remedies encourages major player to offer sugar-free variant

Dutch consumers are becoming increasingly aware of the sugar content of cough/cold remedies. This is prompting major players such as Sanofi-Aventis, which owns leading cough remedy brand Bisolvon to launch sugar-free versions in response to these growing concerns.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Cough, Cold and Allergy (Hay Fever) Remedies in the Netherlands

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Cough, Cold and Allergy (Hay Fever) Remedies industry in Netherlands with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Cough, Cold and Allergy (Hay Fever) Remedies industry in Netherlands, our research will save you time and money while empowering you to make informed, profitable decisions.

The Cough, Cold and Allergy (Hay Fever) Remedies in Netherlands market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Cough, Cold and Allergy (Hay Fever) Remedies in Netherlands?
  • What are the major brands in Netherlands?
  • What is the impact of influenza vaccinations on the sales of cough and cold products?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Cough, Cold and Allergy (Hay Fever) Remedies in the Netherlands - Category analysis

HEADLINES

PROSPECTS

Less severe flu season in 2019 leads to weaker demand for relevant products
Rising incidence of hay fever continue to support performance of antihistamines/allergy remedies
Solid presence for private label with potential for further penetration

COMPETITIVE LANDSCAPE

Lofthouse retains overall leadership, present in largest category of medicated confectionery
Otrivin remains dominant leader of nasal sprays but loses share to natural positioning of competing brand A Vogel
Concerns over sugar content of cough remedies encourages major player to offer sugar-free variant

CATEGORY DATA

Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2014-2019
Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2015-2019
Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2016-2019
Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2019-2024
Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2019-2024

Consumer Health in the Netherlands - Industry Overview

EXECUTIVE SUMMARY

Rising disposable incomes and higher VAT leads to stable current value growth for consumer health
Some products removed from basic health insurance as government encourages self-care amongst local population
GSK Consumer Healthcare takes over leadership of consumer health, now representing former Pfizer brands
Internet retailing continues to rapidly gain share supported by increasing popularity of online players
Marginally stronger value performance predicted for consumer health

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019

DEFINITIONS

SOURCES

Summary 2 Research Sources